Rituxan / MabThera 500 mg Alternative – Relyto (Rituximab) 500 mg IV infusion | Incepta Pharmaceuticals

Relyto 500 mg (Rituximab) IV infusion is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Rituxan / MabThera (Roche / Genentech).

Pack: 1 vial. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.

Description

Product Overview

Relyto 500 mg is listed in the supplied Lucent product catalogue. Its proposed active ingredient is Rituximab, in iv infusion form. The manufacturer’s product labeling should be consulted for the final specification.

Relyto vs Rituxan / MabThera – Reference Brand Comparison

Rituxan / MabThera is a recognized reference brand associated with Roche / Genentech. Relyto is listed on the supplied Lucent products price sheet, attributed by the customer to Incepta Pharmaceuticals Ltd. Matching an active ingredient does not demonstrate bioequivalence, regulatory approval or permission to substitute. Biologic products require particular attention to product-specific authorization, handling and interchangeability.

Composition and Product Details

  • Listed brand: Relyto
  • Generic: Rituximab
  • Strength: 500 mg
  • Dosage form: IV infusion
  • Catalogue pack: 1 vial
  • Attributed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh

Therapeutic Uses and Indications

Rituximab is used in selected B-cell lymphomas, leukemias and certain autoimmune diseases. These are generic-medicine contexts, not independently confirmed approvals for this particular branded presentation. Exact eligible conditions, biomarkers and combination therapies must be confirmed from the local authorized label.

Mechanism of Action

Rituximab targets CD20 on B cells and causes B-cell depletion. Individual treatment response depends on the disease, formulation, dosing and patient factors.

Dosage and Administration

The stated 500 mg refers to the strength of the supplied product, not a recommended daily or treatment dose. Administration schedules, preparation, food instructions and monitoring depend on the approved indication and formulation. Parenteral administration must follow the official preparation and administration protocol under trained healthcare supervision. Never change strength or substitute a brand without medical advice.

Contraindications

Contraindications can include hypersensitivity and other medicine-specific conditions. Review the current prescribing information for all absolute restrictions, including relevant pregnancy-related contraindications.

Warnings and Precautions

Potential serious risks and monitoring requirements vary by medicine. Discuss infections, cardiovascular disease, liver and kidney function, other medications and pregnancy plans with the specialist. The official product leaflet determines the required safety monitoring.

Possible Side Effects

Adverse reactions may involve gastrointestinal symptoms, fatigue, laboratory abnormalities, infections or organ-specific toxicity, depending on the active ingredient. The full medicine-specific adverse effect profile, frequency and emergency warning signs must be reviewed in the authorized prescribing information.

Drug Interactions

Prescription drugs, nonprescription medicines, herbal products and some foods may interact with Rituximab. A pharmacist or specialist should review all current medicines before treatment.

Pregnancy and Breastfeeding

Some treatments can cause fetal harm or require interruption of breastfeeding. Consult the product-specific label and treating specialist for pregnancy testing, contraception and breastfeeding guidance.

Storage and Handling

Follow the temperature, light protection, cold-chain and handling requirements printed on the actual pack. Do not assume storage conditions from another brand or formulation.

Why Is Relyto Listed as an Alternative to Rituxan / MabThera?

The comparison is provided for product discovery by active ingredient and reference brand. It does not establish pharmaceutical or therapeutic equivalence, biosimilarity, interchangeability or authorization in any country.

Manufacturer Information

Listed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Reference brand: Rituxan / MabThera
Reference company: Roche / Genentech
Generic: Rituximab
Strength: 500 mg
Pack: 1 vial

Frequently Asked Questions

What does Relyto contain?

Rituximab 500 mg, subject to confirmation against the official brand-specific label.

Is Relyto the same as Rituxan / MabThera?

No automatic equivalence or interchangeability can be inferred from the generic ingredient alone.

Can I use another strength instead?

Only when an authorized clinician specifically directs it.

Is a prescription required?

Yes. Appropriate prescription and specialist supervision are required.

Important Medical Disclaimer

Educational product identification only. Clinical information and product availability require verification against official labeling and destination-country regulatory requirements. No purchase or treatment decision should be based on this page alone.

Additional information
Generic NameRituximab
Strength500 mg
ManufacturerIncepta Pharmaceuticals Ltd.
Pack Size1 vial
Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Rituxan / MabThera 500 mg Alternative – Relyto (Rituximab) 500 mg IV infusion | Incepta Pharmaceuticals”

Your email address will not be published. Required fields are marked *

Shipping & Delivery